Julie Le Naour

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Venues

Oncoimmunology

The Journal of experimental medicine

Cancer discovery

Université Paris Diderot / Institut Pasteur (MSC)

This page only lists publications with an associated author ORCID identifier.

Education History

Université Paris Diderot / Institut Pasteur Sep 03 2016 - Jul 15 2018

France

MSC

Publications

Julie Le Naour, Guido Kroemer
Trial watch: Toll-like receptor ligands in cancer therapy. Oncoimmunology 12 (1) (2023)
Julie Le Naour, Guido Kroemer
Trial watch: Toll-like receptor ligands in cancer therapy. Oncoimmunology 12 (1) (2023)
Julie Le Naour, Zsófia M Sztupinszki, Vincent Carbonnier, Odile Casiraghi, Virginie Marty, Lorenzo Galluzzi, Zoltan Szallasi, Guido Kroemer, Erika Vacchelli
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. Oncoimmunology 11 (1) (2022)
Juliette Paillet, Céleste Plantureux, Sarah Lévesque, Julie Le Naour, Gautier Stoll, Allan Sauvat, Pamela Caudana, Jimena Tosello, Norma Bloy, Sylvie Lachkar, Isabelle Martins, Paule Opolon, Andrea Checcoli, Agathe Delaune, Noémie Robil, Pierre de la Grange, Juliette Hamroune, Franck Letourneur, Gwennhael Autret, Patrick S C Leung, Merrill Eric Gershwin, Jie S Zhu, Mark J Kurth, Bouchra Lekbaby, Jérémy Augustin, Youra Kim, Shashi Gujar, Cédric Coulouarn, Laura Fouassier, Laurence Zitvogel, Eliane Piaggio, Chantal Housset, Patrick Soussan, Maria Chiara Maiuri, Guido Kroemer, Jonathan G Pol
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. The Journal of experimental medicine 218 (10) (2021)
Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi, Guido Kroemer, Jonathan G Pol
Trial watch: intratumoral immunotherapy. Oncoimmunology 10 (1) (2021)
Zsófia M Sztupinszki, Julie Le Naour, Erika Vacchelli, Pierre Laurent-Puig, Suzette Delaloge, Zoltan Szallasi, Guido Kroemer
A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncoimmunology 10 (1) (2021)
Adriana Petrazzuolo, Julie Le Naour, Erika Vacchelli, Pascale Gaussem, Syrine Ellouze, Georges Jourdi, Eric Solary, Michaela Fontenay, David M Smadja, Guido Kroemer
No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19. Oncoimmunology 9 (1) (2020)
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli, Guido Kroemer
Trial watch: STING agonists in cancer therapy. Oncoimmunology 9 (1) (2020)
Giorgio Frega, Qi Wu, Julie Le Naour, Erika Vacchelli, Lorenzo Galluzzi, Guido Kroemer, Oliver Kepp
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology 9 (1) (2020)
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 9 (1) (2020)
Julie Le Naour, Peng Liu, Liwei Zhao, Sandy Adjemian, Zsofia Sztupinszki, Julien Taieb, Claire Mulot, Aymeric Silvin, Charles-Antoine Dutertre, Florent Ginhoux, Allan Sauvat, Giulia Cerrato, Francesca Castoldi, Isabelle Martins, Gautier Stoll, Juliette Paillet, Khady Mangane, Cornelia Richter, Oliver Kepp, Maria Chiara Maiuri, Federico Pietrocola, Peter Vandenabeele, Fabrice Andre, Suzette Delaloge, Zoltan Szallasi, Pierre Laurent-Puig, Jessica Zucman-Rossi, Laurence Zitvogel, Jonathan G Pol, Erika Vacchelli, Guido Kroemer
A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer discovery 11 (2) (2020)

Julie Le Naour.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Julie Le Naour